TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04372706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTX-240
Description: Engineered red cells co-expressing 4-1BBL and IL-15TP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTX-240
Description: Engineered red cells co-expressing 4-1BBL and IL-15TP
Study: NCT04064047

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trans rectal ultrasound guided prostate biopsy
Description: The investigators checked visual analogue scale of pain at different time periods: prior to probe insertion, during probe insertion. during probe manipulation in the rectum, during performance of periprostatic nerve block, during actual biopsy collection and at termination of procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trans rectal ultrasound guided prostate biopsy
Description: The investigators checked visual analogue scale of pain at different time periods: prior to probe insertion, during probe insertion. during probe manipulation in the rectum, during performance of periprostatic nerve block, during actual biopsy collection and at termination of procedure.
Study: NCT01558453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin will be administered in a 130 mg/m² dose, 2 hour IV infusion, once every 3 weeks. Each cycle will last 3 weeks, or 21 days. Drug will be administered till progression disease or untolerable adverse event.~NOTE: patients with ≤ 12 months old will receive a 4,3 mg/kg dese (based on a 30 kg/m² conversion; i.e: in a 130 mg/m² dose, divided by 30).
Study: NCT00889525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabergoline
Description: Dose 1 mg/week in divided doses, increased by 1 mg/week every month, to the maximum of 5 mg/week. If response is seen than the dose at which response is seen is continued until the end of the study.
Study: NCT03260296

Intervention type: OTHER
Intervention: self-administered structured questionnaire
Description: Data will be collected by self-administered structured questionnaire. The aim of the study and the way of filling the questionnaire will be explained to the students, and then he/she fills the questionnaire by him/her self.~The questionnaire will assess smartphones addiction and some of its associated factors and its health consequences
Study: NCT02075788

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Commercial white bread

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Corn based products (porridge etc.)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Millet based products (porridge etc.)
Study: NCT01465815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linsitinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linsitinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo planned surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT06256341

Intervention type: OTHER
Intervention: Cell cultivation, Antigen testing
Description: day 10, peripheral blood mononuclear cells were re-stimulated with the virus antigen U54 for 6 hours and, thereafter, stained for surface markers (CD3, CD4, CD8, CD56) and intracytoplasmatic activation markers (IL-2, IFN-γ, TNF-α) for flow cytometric detection of virus-specific T-cells. T-cells with intracytoplasmic expression of activation markers after stimulation with the virus antigen are HHV-6-specific T-cells. This indicated HHV-6 specific cellular immunity.~No more interventions in human except blood sampling, only basic research.

Intervention type: OTHER
Intervention: Cell cultivation, Antigen testing
Description: day 10, peripheral blood mononuclear cells were re-stimulated with the virus antigen U54 for 6 hours and, thereafter, stained for surface markers (CD3, CD4, CD8, CD56) and intracytoplasmatic activation markers (IL-2, IFN-γ, TNF-α) for flow cytometric detection of virus-specific T-cells. T-cells with intracytoplasmic expression of activation markers after stimulation with the virus antigen are HHV-6-specific T-cells. This indicated HHV-6 specific cellular immunity.~No more interventions in human except blood sampling, only basic research.
Study: NCT01152034

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychoeducation group therapy
Description: This program consists of 15 sessions of closed group, with each session lasting 120 minutes, each aims at improving four main issues: illness awareness, early detection of prodromal symptoms and recurrences, treatment adherence, and lifestyle regularity. The program will be in groups of 6-12, conducted by two experienced therapists. The structure of each session consists of 30-40 minutes talk on the topic of the day, followed by an exercise related to the issue and a discussion.
Study: NCT04500886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Description: PEG-rhG-CSF is a sustained-duration form of rhG-CSF, a recombinant methionyl form of human granulocyte colony-stimulating factor (G-CSF), similar to rhG-CSF, PEG-rhG-CSF increases the proliferation and differentiation of neutrophils from committed progenitor cells, induces maturation, and enhances the survival and function of mature neutrophils, resulting in dose-dependent increases in neutrophils.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhG-CSF
Description: rhG-CSF can increase the proliferation and differentiation of neutrophils from committed progenitor cells, induces maturation, and enhances the survival and function of mature neutrophils.
Study: NCT03795727

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MD ring and precontoured sectional matrix by TOR VM
Description: MD ring (separation ring) and precontoured sectional matrix (thickness 0.035mm hard) and a wedge was used to secure matrix in place

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Circumferential matrix and tofflemire retainer by Kerr
Description: Circumferential matrix (thickness 0.038mm) applied by tofflemire retainer and secured in place with wedge
Study: NCT02189512

Intervention type: OTHER
Group type: OTHER
Intervention: blood sampling
Description: cases - blood sampling controles - blood sampling

Intervention type: OTHER
Group type: OTHER
Intervention: blood sampling
Description: cases - blood sampling controles - blood sampling
Study: NCT00572208

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin group
Description: Gabapentin group:~Preoperative (2 h before surgery): Tablet Gabapentin 1200 mg (blinded)~1. st Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)~2. nd Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)~3. rd Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)~4. th Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)~5. th Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)
Study: NCT00265473

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Islets of Langerhans
Description: Intraportal infusion of islets of Langerhans
Study: NCT04095507

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: uterocervical angle
Description: uterocervical angle is the angle between lower segment of uterus and cervix
Study: NCT01024296

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Port Close
Description: Device for applying loop suture to close surgical site
Study: NCT04064047

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trans rectal ultrasound guided prostate biopsy
Description: The investigators checked visual analogue scale of pain at different time periods: prior to probe insertion, during probe insertion. during probe manipulation in the rectum, during performance of periprostatic nerve block, during actual biopsy collection and at termination of procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trans rectal ultrasound guided prostate biopsy
Description: The investigators checked visual analogue scale of pain at different time periods: prior to probe insertion, during probe insertion. during probe manipulation in the rectum, during performance of periprostatic nerve block, during actual biopsy collection and at termination of procedure.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Trans rectal ultrasound
Description: Performing a prostate biopsy using a transrectal ultrasound probe - the BK pro focus 2202 transrectal ultrasound and the 8808 bi-plane transrectal probe
Study: NCT02635412

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Scheduled timing of delivery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Scheduled timing of delivery
Study: NCT01471743

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Impact Advance Recovery (R)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ensure Plus (R)
Study: NCT04064047

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trans rectal ultrasound
Description: Performing a prostate biopsy using a transrectal ultrasound probe - the BK pro focus 2202 transrectal ultrasound and the 8808 bi-plane transrectal probe

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trans rectal ultrasound
Description: Performing a prostate biopsy using a transrectal ultrasound probe - the BK pro focus 2202 transrectal ultrasound and the 8808 bi-plane transrectal probe
Study: NCT03908450

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PTCA of coronary de novo lesion PCB
Description: PTCA of coronary de novo lesion with drug coated balloon

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTCA of coronary de novo lesion SCB
Description: PTCA of coronary de novo lesion with drug coated balloon
Study: NCT00247312

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Pd-103
Study: NCT04064047

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trans rectal ultrasound
Description: Performing a prostate biopsy using a transrectal ultrasound probe - the BK pro focus 2202 transrectal ultrasound and the 8808 bi-plane transrectal probe

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trans rectal ultrasound
Description: Performing a prostate biopsy using a transrectal ultrasound probe - the BK pro focus 2202 transrectal ultrasound and the 8808 bi-plane transrectal probe

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trans rectal ultrasound
Description: Performing a prostate biopsy using a transrectal ultrasound probe - the BK pro focus 2202 transrectal ultrasound and the 8808 bi-plane transrectal probe

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trans rectal ultrasound
Description: Performing a prostate biopsy using a transrectal ultrasound probe - the BK pro focus 2202 transrectal ultrasound and the 8808 bi-plane transrectal probe

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Prostate biopsy
Description: Prostate biopsy guided by a transrectal ultrasound with an 18 gauge needle

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prostate biopsy
Description: Prostate biopsy guided by a transrectal ultrasound with an 18 gauge needle
Study: NCT04069819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol 50 MG Oral Tablet
Description: Escitalopram,Selective serotonin reuptake inhibitor- Cilostazol, a selective phosphodiesterase 3 (PDE3) inhibitor, acts as an antiplatelet agent and has been widely approved for treatment of intermittent claudication with peripheral arterial disease and for secondary prevention of ischemic stroke.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram 20 mg tablet once daily for 6 week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram 20 mg tablet once daily for 6 week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT04064047

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prostate biopsy
Description: Prostate biopsy guided by a transrectal ultrasound with an 18 gauge needle

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prostate biopsy
Description: Prostate biopsy guided by a transrectal ultrasound with an 18 gauge needle

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prostate biopsy
Description: Prostate biopsy guided by a transrectal ultrasound with an 18 gauge needle

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prostate biopsy
Description: Prostate biopsy guided by a transrectal ultrasound with an 18 gauge needle

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prostate biopsy
Description: Prostate biopsy guided by a transrectal ultrasound with an 18 gauge needle

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Periprostatic nerve block
Description: Performing a bilateral peri-prostatic nerve block with 10 mL of 1% lidocaine (5 mL on each side)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periprostatic nerve block
Description: Performing a bilateral peri-prostatic nerve block with 10 mL of 1% lidocaine (5 mL on each side)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periprostatic nerve block
Description: Performing a bilateral peri-prostatic nerve block with 10 mL of 1% lidocaine (5 mL on each side)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periprostatic nerve block
Description: Performing a bilateral peri-prostatic nerve block with 10 mL of 1% lidocaine (5 mL on each side)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periprostatic nerve block
Description: Performing a bilateral peri-prostatic nerve block with 10 mL of 1% lidocaine (5 mL on each side)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periprostatic nerve block
Description: Performing a bilateral peri-prostatic nerve block with 10 mL of 1% lidocaine (5 mL on each side)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periprostatic nerve block
Description: Performing a bilateral peri-prostatic nerve block with 10 mL of 1% lidocaine (5 mL on each side)
Study: NCT04208152

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anle138b
Description: capsule containing excipient and anle138b

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo capsule containing excipient
Study: NCT01365780

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Oxygen Therapy
Description: The patients receive 10 sessions of HBOT in two weeks, starting on the day after the surgical treatment of their radius fracture. Each session lasts about one hour.
Study: NCT01921179

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GOALS (Goal-Oriented Attentional Regulation)
Description: Goal-Oriented Attentional Regulation (GOALS) will involve 5-weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of home practice). Some subjects will only receive the GOALS intervention.
Study: NCT01365026

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PVS: Programa de Vida Saludable
Description: Lifestyle counseling and prescription
Study: NCT02255968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-788
Description: EDP-788 Capsules. All interventions are given as multiple doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules. All interventions are given as multiple doses
Study: NCT01648517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: A1: docetaxel 60mg/m2 on Day 1 vinorelbine 20mg/m2 on Day 1 and Day 8 (DV) A2: gemcitabine 1000mg/m2 on Day 1 vinorelbine 25mg/m2 on Day 1 and Day 8 (GV) A3: docetaxel 75mg/m2 on Day 1 carboplatin AUC5 on Day 1 (DC) A4: gemcitabine 1000mg/m2 on Day 1 and 8 carboplatin AUC5 on Day 1 (GC)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Description: Drug: Docetaxel 75mg/m2 IV on Day 1 Drug: Carboplatin AUC5 IV on Day 1
Study: NCT01597973

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: colistin and meropenem
Description: colistin standard loading dose, maintenance dose based on patients renal function meropenem- dose based on patients renal function

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: colistin and placebo
Description: colistin- loading dose standard, maintenance dosed based on patients renal function placebo- mimic meropenem (blinded)
Study: NCT00578266

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide,Campath IH and TBI
Description: DAY 5 TREATMENT~* 6 5 CYTOXAN 50 mg/kg WITH MESNA~* 5 CYTOXAN 50 mg/kg WITH MESNA;~* 4 CYTOXAN 50 mg/kgWITH MESNA; CAMPATH 3-10 mg~* 3 CYTOXAN 50 mg/kg WITH MESNA; CAMPATH;~* 2 TBI; CAMPATH; TACROLIMUS~* 1 TBI (second fraction); CAMPATH (am) 0 STEM CELL INFUSION (pm)
Study: NCT03126448

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Highly Sensitive Assays
Description: Tissue will be collected at the time of surgery from patients in each arm of the study. In addition to tissue stored in RNAlater and sent to a research laboratory, cultures will also be sent to Quest Diagnostics for independent culture results.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Highly Sensitive Assays
Description: Tissue will be collected at the time of surgery from patients in each arm of the study. In addition to tissue stored in RNAlater and sent to a research laboratory, cultures will also be sent to Quest Diagnostics for independent culture results.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Highly Sensitive Assays
Description: Tissue will be collected at the time of surgery from patients in each arm of the study. In addition to tissue stored in RNAlater and sent to a research laboratory, cultures will also be sent to Quest Diagnostics for independent culture results.
Study: NCT01599091

Intervention type: OTHER
Intervention: Specimens collection
Description: Tooth extraction will be preformed in the regular way regardless of the study. Patients will be asked permission to obtain the extracted tooth and excess of gingival remnants for further in vitro investigation in the main investigator's laboratory.
Study: NCT01921179

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EDU (Brain Health Education)
Description: Brain Health Education (EDU) will involve 5-weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of homework). The EDU intervention involves education on brain health and functioning in a classroom format, with study materials for homework. Some subjects will start with EDU and then cross-over to the GOALS.
Study: NCT00051246

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mother-Infant Group Psychotherapy
Description: Mother-infant group psychotherapy consists of weekly 2.5-hour psychotherapy sessions comprised of mother's group therapy, infant developmental therapy, and mother-infant dyadic psychotherapy. Group treatment will last 15 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interpersonal Psychotherapy
Description: Individual psychotherapy treatment focuses on role transition, interpersonal relationships, and loss. Individual treatment period will last 15 weeks.
Study: NCT01927575

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard X-Ray + CT
Description: Standard of Care X-Ray Imaging + CT
Study: NCT02577107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conbercept
Study: NCT01150929

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: P.F.C. Sigma knee arthroplasty
Description: Randomization to either rotating platform or fixed bearing tibial plateau and polyethylene

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: P.F.C. Sigma knee arthroplasty
Description: Randomization to either rotating platform or fixed bearing tibial plateau and polyethylene
Study: NCT03356496

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AirLife 4000 cc incentive spirometry device
Description: Incentive spirometry device provides improved lung expansion and respiratory muscle strength
Study: NCT03072966

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable device (Fitbit Charge HR® or Fitbit Alta ®)
Description: Physical activities will be monitored by wearable device.
Study: NCT01520116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stage 1 - ATS907 - Dose 1
Description: QD and/or BID dosing for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stage 1 - ATS907 - Dose 2
Description: QD and/or BID dosing for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stage 1 - ATS907 - Dose 3
Description: QD and/or BID dosing for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stage 1 - ATS907 - Dose 4
Description: QD and/or BID dosing for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Stage 1 - Vehicle
Description: QD and/or BID dosing for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stage 2 - ATS907 - Dose A - to be selected based on Stage 1
Description: QD and/or BID dosing for 4 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stage 2 - ATS907 - Dose B - to be selected based on Stage 1
Description: QD and/or BID dosing for 4 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timoptic
Description: 0.5%
Study: NCT06030167

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Insecure attachment and psychosocial functioning in autistic adults
Description: Questionaires about attachment, psychosocial functioning, depressive symptoms, paranoid ideation, and emotion regulation were administered to 83 autistic adults (50 males, 33 females).